与慢性肾脏病相关的血脂异常
Dyslipidemia associated with chronic kidney disease.
作者信息
Tsimihodimos Vasilis, Mitrogianni Zoi, Elisaf Moses
机构信息
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
出版信息
Open Cardiovasc Med J. 2011;5:41-8. doi: 10.2174/1874192401105010041. Epub 2011 Feb 24.
Abstract
Cardiovascular disease is a major cause of morbidity and mortality in patients with impaired renal function. Dyslipidemia has been established as a well-known traditional risk factor for cardiovascular disease (CVD) in the general population and it is well known that patients with chronic kidney disease (CKD) exhibit significant alterations in lipoprotein metabolism. In this review, the pathogenesis and treatment of CKD-induced dyslipidemia are discussed. Studies on lipid abnormalities in predialysis, hemodialysis and peritoneal dialysis patients are analyzed. In addition, the results of the studies that tested the effects of the hypolipidemic drugs on cardiovascular morbidity and mortality in patients with CKD are reported.
摘要
心血管疾病是肾功能受损患者发病和死亡的主要原因。血脂异常已被确认为普通人群中众所周知的心血管疾病（CVD）传统危险因素，并且众所周知，慢性肾脏病（CKD）患者的脂蛋白代谢存在显著改变。在本综述中，将讨论CKD诱导的血脂异常的发病机制和治疗。分析了关于透析前、血液透析和腹膜透析患者脂质异常的研究。此外，还报告了测试降血脂药物对CKD患者心血管发病率和死亡率影响的研究结果。
相似文献
1
Dyslipidemia associated with chronic kidney disease.与慢性肾脏病相关的血脂异常
Open Cardiovasc Med J. 2011;5:41-8. doi: 10.2174/1874192401105010041. Epub 2011 Feb 24.
2
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.慢性肾脏病中的血脂异常：发病机制与治疗方法
Am J Nephrol. 2008;28(6):958-73. doi: 10.1159/000144024. Epub 2008 Jul 9.
3
[Dyslipidemia and stroke in patients with chronic kidney disease].[慢性肾脏病患者的血脂异常与中风]
Acta Med Croatica. 2014 Apr;68(2):141-9.
4
Lipid abnormalities in kidney disease and management strategies.肾脏疾病中的脂质异常及管理策略。
World J Nephrol. 2015 Feb 6;4(1):83-91. doi: 10.5527/wjn.v4.i1.83.
5
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.肾脏病相关血脂异常中 PCSK9 和脂蛋白受体的新方面。
Cell Signal. 2019 Mar;55:53-64. doi: 10.1016/j.cellsig.2018.12.001. Epub 2018 Dec 12.
6
Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation.慢性肾脏病及肾移植中的脂蛋白异常
Life (Basel). 2021 Apr 5;11(4):315. doi: 10.3390/life11040315.
7
Statins for treatment of dyslipidemia in chronic kidney disease.他汀类药物用于治疗慢性肾脏病中的血脂异常。
Perit Dial Int. 2006 Sep-Oct;26(5):523-39.
8
Dyslipidemia in Dialysis Patients.透析患者的血脂异常
Semin Dial. 2015 Jul-Aug;28(4):345-53. doi: 10.1111/sdi.12375. Epub 2015 Apr 9.
9
The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.非高密度脂蛋白在管理5期慢性肾脏病血脂异常中的作用
Clin Nephrol. 2006 Nov;66(5):336-47. doi: 10.5414/cnp66336.
10
Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.降脂治疗对终末期肾病需血液透析患者减少心血管事件的影响。
Pharmacotherapy. 2010 Aug;30(8):823-9. doi: 10.1592/phco.30.8.823.
引用本文的文献
1
The Effect of Increased Plant Protein Intake on the Lipid Profile of Chronic Kidney Disease Patients: A Meta-Analysis of Controlled Clinical Trials.增加植物蛋白摄入量对慢性肾脏病患者血脂谱的影响：一项对照临床试验的荟萃分析
Nutrients. 2025 Apr 23;17(9):1408. doi: 10.3390/nu17091408.
2
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions.降脂药物的肾脏安全性评估：介于旧有定论与新问题之间
Drugs. 2025 Mar 19. doi: 10.1007/s40265-025-02158-0.
3
Emerging roles of PCSK9 in kidney disease: lipid metabolism, megalin regulation and proteinuria.前蛋白转化酶枯草溶菌素9在肾脏疾病中的新作用：脂质代谢、巨膜蛋白调节和蛋白尿。
Pflugers Arch. 2025 Jun;477(6):773-786. doi: 10.1007/s00424-025-03069-5. Epub 2025 Feb 18.
4
Comprehensive Review of Lipid Management in Chronic Kidney Disease and Hemodialysis Patients: Conventional Approaches, and Challenges for Cardiovascular Risk Reduction.慢性肾脏病和血液透析患者血脂管理的全面综述：传统方法及降低心血管风险面临的挑战
J Clin Med. 2025 Jan 20;14(2):643. doi: 10.3390/jcm14020643.
5
The importance of paraoxonase 1 activity in chronic kidney disease.对慢性肾脏病患者血清对氧磷酶 1 活性的重视。
Ren Fail. 2024 Dec;46(2):2376930. doi: 10.1080/0886022X.2024.2376930. Epub 2024 Jul 10.
6
ApoB100 and Atherosclerosis: What's New in the 21st Century?载脂蛋白B100与动脉粥样硬化：21世纪有哪些新进展？
Metabolites. 2024 Feb 12;14(2):123. doi: 10.3390/metabo14020123.
7
Adherence to Life's Essential 8 and incident chronic kidney disease: a prospective study of 147,988 UK Biobank participants.坚持生命基本八项与新发慢性肾脏病：对147988名英国生物银行参与者的前瞻性研究
Am J Clin Nutr. 2023 Oct;118(4):804-811. doi: 10.1016/j.ajcnut.2023.08.007. Epub 2023 Aug 19.
8
Transcriptomic analysis identifies novel candidates in cardiorenal pathology mediated by chronic peritoneal dialysis.转录组分析鉴定了慢性腹膜透析介导的心肾病理的新候选物。
Sci Rep. 2023 Jun 21;13(1):10051. doi: 10.1038/s41598-023-36647-7.
9
Statins Have an Anti-Inflammation in CKD Patients: A Meta-Analysis of Randomized Trials.他汀类药物在 CKD 患者中具有抗炎作用：一项随机试验的荟萃分析。
Biomed Res Int. 2022 Oct 22;2022:4842699. doi: 10.1155/2022/4842699. eCollection 2022.
10
Effects of Regular Brazil Nut ( H.B.K.) Consumption on Health: A Systematic Review of Clinical Trials.经常食用巴西坚果（H.B.K.）对健康的影响：临床试验的系统评价
Foods. 2022 Sep 19;11(18):2925. doi: 10.3390/foods11182925.
本文引用的文献
1
Cardiovascular risk factors in patients with chronic kidney disease.慢性肾病患者的心血管危险因素
Nat Rev Cardiol. 2009 Sep;6(9):580-9. doi: 10.1038/nrcardio.2009.121. Epub 2009 Jul 21.
2
Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III.慢性肾病延迟 VLDL-apoB-100 颗粒的代谢分解：载脂蛋白 C-III 的潜在作用。
J Lipid Res. 2009 Dec;50(12):2524-31. doi: 10.1194/jlr.P900003-JLR200. Epub 2009 Jun 21.
3
Dyslipidemia of kidney disease.肾脏疾病的血脂异常
Curr Opin Lipidol. 2009 Aug;20(4):293-9. doi: 10.1097/MOL.0b013e32832dd832.
4
Mechanisms for increased cardiovascular disease in chronic kidney dysfunction.慢性肾功能不全时心血管疾病增加的机制。
Curr Opin Nephrol Hypertens. 2009 May;18(3):181-8. doi: 10.1097/mnh.0b013e328327b360.
5
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.用于非透析慢性肾病患者的HMG辅酶A还原酶抑制剂（他汀类药物）
Cochrane Database Syst Rev. 2009 Apr 15(2):CD007784. doi: 10.1002/14651858.CD007784.
6
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.瑞舒伐他汀与血液透析患者的心血管事件
N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30.
7
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.针对患有冠心病和慢性肾脏病的管理式医疗患者的阿托伐他汀聚焦治疗。
Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025. Epub 2009 Feb 11.
8
Lipid and lipoprotein metabolism in chronic kidney disease.慢性肾脏病中的脂质与脂蛋白代谢
J Ren Nutr. 2009 Jan;19(1):73-7. doi: 10.1053/j.jrn.2008.10.011.
9
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.慢性肾脏病中的血脂异常：发病机制与治疗方法
Am J Nephrol. 2008;28(6):958-73. doi: 10.1159/000144024. Epub 2008 Jul 9.
10
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.阿托伐他汀强化降脂治疗冠心病合并慢性肾脏病患者：TNT（治疗达新目标）研究
J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.
Zotero 插件